Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients

Abstract Purpose This study aimed to determine whether administering intravesical chemotherapy (IVC) during the Bacillus Calmette - Guérin (BCG) waiting period after the second TURBT improves the recurrence-free survival (RFS) of patients with non - muscle - invasive bladder cancer (NMIBC). Methods...

Full description

Bibliographic Details
Published in:	BMC Cancer
Main Authors:	Zhen Li, Zewei Wang, Jiyue Wu, Feilong Zhang, Lijian Gan, Wei Wang, Hailong Li, Ling Gu
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Subjects:	Non–muscle-invasive bladder cancer TURBT BCG Chemotherapy Recurrence
Online Access:	https://doi.org/10.1186/s12885-025-13705-z

Similar Items

IVC treatment between primary and second TURBT may improve the prognosis of high-risk NMIBC patients receiving BCG treatment
by: Zhen Li, et al.
Published: (2025-02-01)

Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients
by: Gabriel GLUCK, et al.
Published: (2020-06-01)

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia
by: Chamodi Pillippu Hewa, et al.
Published: (2024-02-01)

The Urinary Microbiome and Bladder Cancer
by: Nassib Abou Heidar, et al.
Published: (2023-03-01)

Pott's disease post intravesical BCG
by: Anika Jain
Published: (2023-01-01)

Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette‐Guerin perfusion
by: Tao‐nong Cai, et al.
Published: (2023-12-01)

Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
by: Hongda Zhao, et al.
Published: (2021-11-01)

Urinary microbiota changes among NMIBC patients during BCG therapy: comparing BCG responders and non-responders
by: Toni Boban, et al.
Published: (2025-03-01)

Intravesical Explosion Resulting in Bladder Rupture During Transurethral Resection of Bladder Tumors
by: Chih-Chiao Lee, et al.
Published: (2014-12-01)

Protective role of intravesical BCG in COVID-19 severity
by: Héctor Gallegos, et al.
Published: (2021-03-01)

BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies
by: Georgia Bourlotos, et al.
Published: (2024-01-01)

Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer
by: Mohamad Abou Chakra, et al.
Published: (2024-08-01)

Comparison of the efficacy of BCG intravesical immunotherapy using the conventional Rotisserie method with the non-Rotisserie method
by: Mohammad Kazem Hariri, et al.
Published: (2023-10-01)

Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer
by: Mirko Bakula, et al.
Published: (2024-06-01)

Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
by: Oreoluwa Oladiran, et al.
Published: (2020-03-01)

BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
by: Sarah Lidagoster, et al.
Published: (2024-02-01)

Does the Decrease in Neutrophil-lymphocyte Ratio after BCG Treatment Be a Prognostic Marker for NMIBC?
by: Aykut Başer
Published: (2020-12-01)

Bladder paraganglioma: A case of acute respiratory distress syndrome triggered by large bladder tumor transurethral resection with mild symptoms and atypical imaging
by: Toshifumi Takahashi, et al.
Published: (2023-05-01)

Potentiation of the therapeutic effect of intravesical BCG through synthetic and biogenic selenium nanoparticles in a nitrosamine-induced bladder cancer mouse model
by: Ramak Ajideh, et al.
Published: (2022-12-01)

Real‐world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non‐muscle invasive bladder cancer—Implications for global shortage
by: Amandeep Arora, et al.
Published: (2025-06-01)

Intravesical VSVd51-GM-CSF virotherapy is superior to BCG in treating bladder cancer in preclinical and translational models
by: Lauren Daniel, et al.
Published: (2025-09-01)

What have we learned after 30 years of BCG intravesical therapy for superficial bladder cancer?
by: Marcos Tobias-Machado, et al.
Published: (2009-12-01)

When Bladder Cancer Treatment Strikes Back: Mycotic Aneurysms After Intravesical BCG Therapy
by: Sarah Blackwell, et al.
Published: (2025-10-01)

On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC
by: Bernadett E. Szabados, et al.
Published: (2025-04-01)

Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with <i>GMCSF+IFN α </i> Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model
by: Sin Mun Tham, et al.
Published: (2021-11-01)

Transurethral resection of a giant bladder leiomyoma
by: Dihao Deng, et al.
Published: (2025-04-01)

Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value
by: Ali Nebioğlu, et al.
Published: (2024-09-01)

Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain
by: Hideyuki Isobe, et al.
Published: (2025-01-01)

Clinical and Pathological Characteristics of Bladder Cancer in Patients Aged 18–45 Undergoing Transurethral Resection of Bladder Tumor
by: Alexei Croitor, et al.
Published: (2024-10-01)

Urothelial neoplasm in a 19‐year‐old male patient with urine discoloration, negative lab, and imaging workup: Should we investigate the findings or the symptom?
by: Evangelos N. Symeonidis, et al.
Published: (2019-03-01)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
by: Ana T. Vilares, MD, et al.
Published: (2022-07-01)

LEGAL BASIC OF BCG-THERAPY FOR BLADDER CANCER IN MUNICIPAL POLYCLINICS
by: M. M. Zorina, et al.
Published: (2016-10-01)

Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review
by: G. Caramori, et al.
Published: (2015-11-01)

Bladder Preservation With Transurethral Tumor Resection and Intravesical BCG Instillation in Superficial Muscle-Invasive Bladder Cancer: A 10-Year Follow-up
by: Dong Gyun Kim, et al.
Published: (2023-03-01)

Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study
by: Tugay Aksakalli, et al.
Published: (2025-03-01)

Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
by: Arjun Pon Avudaiappan, et al.
Published: (2024-11-01)

Pneumonitis secondary to intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy
by: Komeil Alattar, MBBS, PGCert, et al.
Published: (2025-09-01)

Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters ≥3cm compared to transurethral resection: a non-randomized controlled study
by: Zhipeng Yao, et al.
Published: (2024-10-01)

Psoriasis exacerbation following intravesical BCG immunotherapy for bladder carcinoma: A case report
by: Yusuf Can Edek, et al.
Published: (2025-07-01)

A case of inflammatory myofibroblastic tumor of the urinary bladder with emergency clinical symptoms similar to bladder cancer
by: Yuki Matsui
Published: (2021-09-01)